Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
35.46
+0.77 (2.22%)
At close: Jun 18, 2025, 4:00 PM
35.50
+0.04 (0.11%)
After-hours: Jun 18, 2025, 4:20 PM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover Agios Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $58.6, which forecasts a 65.26% increase in the stock price over the next year. The lowest target is $51 and the highest is $71.
Price Target: $58.6 (+65.26%)
Analyst Consensus: Buy
* Price targets were last updated on May 2, 2025.
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +100.23% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $58 | Strong Buy | Reiterates | $58 | +63.56% | Feb 24, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Dec 18, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $55 → $57 | Buy | Maintains | $55 → $57 | +60.74% | Dec 10, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $53 → $75 | Buy | Maintains | $53 → $75 | +111.51% | Dec 9, 2024 |
Financial Forecast
Revenue This Year
44.64M
from 36.50M
Increased by 22.30%
Revenue Next Year
143.10M
from 44.64M
Increased by 220.58%
EPS This Year
-7.33
from 11.64
EPS Next Year
-6.86
from -7.33
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 58.8M | 218.7M | 556.6M | ||
| Avg | 44.6M | 143.1M | 352.8M | ||
| Low | 38.2M | 91.1M | 171.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 61.1% | 389.9% | 288.9% | ||
| Avg | 22.3% | 220.6% | 146.5% | ||
| Low | 4.7% | 104.2% | 19.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.09 | -5.65 | -2.15 | ||
| Avg | -7.33 | -6.86 | -4.37 | ||
| Low | -7.55 | -8.18 | -8.82 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.